Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX Other stock markets 11:34:36 2025-01-14 am EST			5-day change	1st Jan Change
26.60 ^USD	-2.81%		-7.20%	-9.66%

Dec. 02	HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	MT
Dec. 02	NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint	MT

Highlights

NovoCure Limited Reports Preliminary Revenue Results for the Fourth Quarter and Full Year Ended December 31, 2024	Jan. 13	CI
HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating	Dec. 02	MT
NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint	Dec. 02	MT
Leerink Partners Adjusts NovoCure Price Target to $33 From $28, Maintains Outperform Rating	Dec. 02	MT
Evercore ISI Upgrades NovoCure to Outperform	Dec. 02	MT
Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields Therapy for Pancreatic Cancer	Dec. 02	CI
NovoCure Q3 Loss Narrows, Net Revenue Increases	24-10-30	MT
Earnings Flash (NVCR) NOVOCURE Posts Q3 Revenue $155.1M	24-10-30	MT
Earnings Flash (NVCR) NOVOCURE Posts Q3 Loss $-0.28	24-10-30	MT
Earnings Flash (NVCR) NOVOCURE Posts Q3 Loss $-0.28 Per Share	24-10-30	MT
NovoCure Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	24-10-30	CI
Exchange-Traded Funds, Equity Futures Higher Pre-Bell Wednesday as Big Banks Gather Investors' Confidence	24-10-16	MT
Sector Update: Health Care Stocks Rise Premarket Wednesday	24-10-16	MT
Sector Update: Health Care	24-10-16	MT
Top Premarket Gainers	24-10-16	MT
HC Wainwright Upgrades NovoCure to Buy From Neutral, Adjusts Price Target to $30 From $24	24-10-16	MT
North American Morning Briefing : Stock Futures Muted Ahead of Heavy Earnings Schedule	24-10-16	DJ
Novocure Shares Rise After FDA Approves Optune Lua Cancer Treatment	24-10-15	DJ
NovoCure Says US FDA Approves Optune Lua to Treat Lung Cancer; Shares Jump After Hours	24-10-15	MT
FDA Approves Novocure's Optune Lua® for the Treatment of Metastatic Non-Small Cell Lung Cancer	24-10-15	CI
NovoCure Q2 Loss Narrows, Net Revenue Increases	24-07-25	MT
Earnings Flash (NVCR) NOVOCURE Posts Q2 Revenue $150.4M, vs. Street Est of $135.8M	24-07-25	MT
Earnings Flash (NVCR) NOVOCURE Reports Q2 Loss $-0.31 Per Share, vs. Street Est of Loss $-0.40 Per Share	24-07-25	MT
NovoCure Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024	24-07-25	CI
Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial	24-06-03	CI

Become a member to access more news.

100% Free Registration

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Medical Equipment, Supplies & Distribution

Highlights

Filters